Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

99mTc-3PRGD2 SPECT/CT Imaging for Diagnosing Lymph Node Metastasis of Primary Malignant Lung Tumors

  • Liming Xiao (Department of Nuclear Medicine, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China) ;
  • Shupeng Yu (Department of Nuclear Medicine, Shengjing Hospital of China Medical University) ;
  • Weina Xu (Department of Nuclear Medicine, Shengjing Hospital of China Medical University) ;
  • Yishan Sun (Department of Nuclear Medicine, Shengjing Hospital of China Medical University) ;
  • Jun Xin (Department of Nuclear Medicine, Shengjing Hospital of China Medical University)
  • Received : 2023.05.04
  • Accepted : 2023.08.22
  • Published : 2023.11.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To evaluate 99mtechnetium-three polyethylene glycol spacers-arginine-glycine-aspartic acid (99mTc-3PRGD2) single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging for diagnosing lymph node metastasis of primary malignant lung neoplasms. Materials and Methods: We prospectively enrolled 26 patients with primary malignant lung tumors who underwent 99mTc-3PRGD2 SPECT/CT and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT imaging. Both imaging methods were analyzed in qualitative (visual dichotomous and 5-point grades for lymph nodes and lung tumors, respectively) and semiquantitative (maximum tissue-to-background radioactive count) manners for the lymph nodes and lung tumors. The performance of the differentiation of lymph nodes with and without metastasis was determined at the per-lymph node station and per-patient levels using histopathological results as the reference standard. Results: Total 42 stations had metastatic lymph nodes and 136 stations had benign lymph nodes. The differences between metastatic and benign lymph nodes in the visual qualitative and semiquantitative analyses of 99mTc-3PRGD2 SPECT/CT and 18F-FDG PET/CT were statistically significant (all P < 0.001). The area under the receiver operating characteristic curve (AUC) in the semi-quantitative analysis of 99mTc-3PRGD2 SPECT/CT was 0.908 (95% confidence interval [CI], 0.851-0.966), and the sensitivity, specificity, positive predictive value, and negative predictive value were 0.86 (36/42), 0.88 (120/136), 0.69 (36/52), and 0.95 (120/126), respectively. Among the 26 patients (including two patients each with two lung tumors), 15 had pathologically confirmed lymph node metastasis. The difference between primary lung lesions in patients with and without lymph node metastasis was statistically significant only in the semi-quantitative analysis of 99mTc-3PRGD2 SPECT/CT (P = 0.007), with an AUC of 0.807 (95% CI, 0.641-0.974). Conclusion: 99mTc-3PRGD2 SPECT/CT imaging may notably perform in the direct diagnosis of lymph node metastasis of primary malignant lung tumors and indirectly predict the presence of lymph node metastasis through uptake in the primary lesions.

Keywords

Acknowledgement

The authors thank all their coworkers involved in the study for their support and assistance.

References

  1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17-48 https://doi.org/10.3322/caac.21763
  2. Kudo S, Imai K, Ishiyama K, Hashimoto M, Saito H, Motoyama S, et al. New CT criteria for nodal staging in non-small cell lung cancer. Clin Imaging 2014;38:448-453 https://doi.org/10.1016/j.clinimag.2014.02.008
  3. Xia Y, Zhang B, Zhang H, Li W, Wang KP, Shen H. Evaluation of lymph node metastasis in lung cancer: who is the chief justice? J Thorac Dis 2015;7(Suppl 4):S231-S237
  4. Liao X, Liu M, Li S, Huang W, Guo C, Liu J, et al. The value on SUV-derived parameters assessed on 18F-FDG PET/CT for predicting mediastinal lymph node metastasis in non-small cell lung cancer. BMC Med Imaging 2023;23:49
  5. Marcus C, Tajmir SH, Rowe SP, Sheikhbahaei S, Solnes LB. 18F-FDG PET/CT for response assessment in lung cancer. Semin Nucl Med 2022;52:662-672 https://doi.org/10.1053/j.semnuclmed.2022.04.001
  6. Sun Y, Xiao L, Wang Y, Liu C, Cao L, Zhai W, et al. Diagnostic value of dynamic 18F-FDG PET/CT imaging in non-small cell lung cancer and FDG hypermetabolic lymph nodes. Quant Imaging Med Surg 2023;13:2556-2567
  7. Bille A, Pelosi E, Skanjeti A, Arena V, Errico L, Borasio P, et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg 2009;36:440-445 https://doi.org/10.1016/j.ejcts.2009.04.003
  8. Xiao L, Xin J. Advances in clinical oncology research on 99mTc-3PRGD2 SPECT imaging. Front Oncol 2022;12:898764
  9. Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp Cell Res 2006;312:651-658 https://doi.org/10.1016/j.yexcr.2005.10.020
  10. Niu G, Chen X. Why integrin as a primary target for imaging and therapy. Theranostics 2011;1:30-47 https://doi.org/10.7150/thno/v01p0030
  11. Zhu Z, Miao W, Li Q, Dai H, Ma Q, Wang F, et al. 99mTc3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med 2012;53:716-722 https://doi.org/10.2967/jnumed.111.098988
  12. Chen Z, Fu F, Li F, Zhu Z, Yang Y, Chen X, et al. Comparison of [99mTc]3PRGD2 imaging and [18F]FDG PET/CT in breast cancer and expression of integrin αvβ3 in breast cancer vascular endothelial cells. Mol Imaging Biol 2018;20:846-856 https://doi.org/10.1007/s11307-018-1178-y
  13. Zheng S, Chen Z, Huang C, Chen Y, Miao W. [99mTc]3PRGD2 for integrin receptor imaging of esophageal cancer: a comparative study with [18F]FDG PET/CT. Ann Nucl Med 2019;33:135-143 https://doi.org/10.1007/s12149-018-1315-3
  14. Jin X, Liang N, Wang M, Meng Y, Jia B, Shi X, et al. Integrin imaging with 99mTc-3PRGD2 SPECT/CT shows high specificity in the diagnosis of lymph node metastasis from non-small cell lung cancer. Radiology 2016;281:958-966 https://doi.org/10.1148/radiol.2016150813
  15. Lv N, Gao S, Bai L, Ji B, Xue J, Ge X, et al. Advantages of 99mTc-3PRGD2 SPECT over CT in the preoperative assessment of lymph node metastasis in patients with esophageal cancer. Ann Nucl Med 2019;33:39-46 https://doi.org/10.1007/s12149-018-1300-x
  16. Watanabe S. Lymph node dissection for lung cancer: past, present, and future. Gen Thorac Cardiovasc Surg 2014;62:407-414 https://doi.org/10.1007/s11748-014-0412-z
  17. Felding-Habermann B, Fransvea E, O'Toole TE, Manzuk L, Faha B, Hensler M. Involvement of tumor cell integrin αvβ3 in hematogenous metastasis of human melanoma cells. Clin Exp Metastasis 2002;19:427-436 https://doi.org/10.1023/A:1016377114119
  18. Li M, Wang Y, Li M, Wu X, Setrerrahmane S, Xu H. Integrins as attractive targets for cancer therapeutics. Acta Pharm Sin B 2021;11:2726-2737 https://doi.org/10.1016/j.apsb.2021.01.004
  19. Shi J, Wang L, Kim YS, Zhai S, Liu Z, Chen X, et al. Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem 2008;51:7980-7990 https://doi.org/10.1021/jm801134k
  20. Jia B, Liu Z, Zhu Z, Shi J, Jin X, Zhao H, et al. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin αvβ3-selective radiotracer 99mTc-3PRGD 2 in non-human primates. Mol Imaging Biol 2011;13:730-736 https://doi.org/10.1007/s11307-010-0385-y